JP2007523930A - ピペリジン誘導体 - Google Patents
ピペリジン誘導体 Download PDFInfo
- Publication number
- JP2007523930A JP2007523930A JP2007500098A JP2007500098A JP2007523930A JP 2007523930 A JP2007523930 A JP 2007523930A JP 2007500098 A JP2007500098 A JP 2007500098A JP 2007500098 A JP2007500098 A JP 2007500098A JP 2007523930 A JP2007523930 A JP 2007523930A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- formula
- treatment
- compounds
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 11
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 7
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 7
- 208000032841 Bulimia Diseases 0.000 claims abstract description 6
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 6
- 208000030814 Eating disease Diseases 0.000 claims abstract description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 6
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 6
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 6
- 239000002400 serotonin 2A antagonist Substances 0.000 claims abstract description 6
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 5
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 5
- 208000022531 anorexia Diseases 0.000 claims abstract description 5
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 5
- 206010027175 memory impairment Diseases 0.000 claims abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- -1 racemates Chemical class 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010033664 Panic attack Diseases 0.000 claims description 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HHLHIZHPWGGVSY-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-(1h-indol-7-yl)methanol Chemical compound C=1C=CC=2C=CNC=2C=1C(O)C(CC1)CCN1CCC1=CC=C(F)C=C1 HHLHIZHPWGGVSY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BVHCCXBFHAXYPT-UHFFFAOYSA-N 2-(4-fluorophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=C(F)C=C1 BVHCCXBFHAXYPT-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- XWACQQVGBWRNLS-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-(1h-indol-7-yl)methanone Chemical class C1=CC(F)=CC=C1CCN1CCC(C(=O)C=2C=3NC=CC=3C=CC=2)CC1 XWACQQVGBWRNLS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- JIEHVFDROZTWNM-UHFFFAOYSA-N 1-[7-[dimethylamino-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methyl]-1h-indol-3-yl]-2,2,2-trifluoroethanone Chemical compound C=1C=CC=2C(C(=O)C(F)(F)F)=CNC=2C=1C(N(C)C)C(CC1)CCN1CCC1=CC=C(F)C=C1 JIEHVFDROZTWNM-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- VRBCYGRZFFWAOX-UHFFFAOYSA-N 1h-indol-7-yl(piperidin-4-yl)methanol Chemical compound C=1C=CC=2C=CNC=2C=1C(O)C1CCNCC1 VRBCYGRZFFWAOX-UHFFFAOYSA-N 0.000 description 1
- WYMUSJXGPLLTMI-UHFFFAOYSA-N 2,2,2-trifluoro-1-[7-[[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-hydroxymethyl]-1h-indol-3-yl]ethanone Chemical compound C=1C=CC=2C(C(=O)C(F)(F)F)=CNC=2C=1C(O)C(CC1)CCN1CCC1=CC=C(F)C=C1 WYMUSJXGPLLTMI-UHFFFAOYSA-N 0.000 description 1
- WNBOFRORKHXRTO-UHFFFAOYSA-N 2,3-dihydro-1h-indol-7-yl(piperidin-4-yl)methanol Chemical compound C=1C=CC=2CCNC=2C=1C(O)C1CCNCC1 WNBOFRORKHXRTO-UHFFFAOYSA-N 0.000 description 1
- FDYRVWHYMFPGGF-UHFFFAOYSA-N 2,3-dihydro-1h-indol-7-yl-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound C=1C=CC=2CCNC=2C=1C(O)C(CC1)CCN1CCC1=CC=C(F)C=C1 FDYRVWHYMFPGGF-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- JIXGHXKIJFGPCF-UHFFFAOYSA-N 7-[1-[2-(4-fluorophenyl)ethyl]piperidine-4-carbonyl]-1h-indole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CCN1CCC(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 JIXGHXKIJFGPCF-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- BGHDUTQZGWOQIA-VQSKNWBGSA-N Ergovaline Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C)C2)=C3C2=CNC3=C1 BGHDUTQZGWOQIA-VQSKNWBGSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000006906 Vascular Ring Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BGHDUTQZGWOQIA-RKUMIMICSA-N ergovaline Natural products O=C(N[C@@]1(C)C(=O)N2[C@H](C(C)C)C(=O)N3[C@@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23 BGHDUTQZGWOQIA-RKUMIMICSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Xは、HまたはF、Cl、Br、I、CN、OCN、SCN、COR2、COOR2、C ONR2R3、イミダゾリル、ピラゾリル、トリアゾリル、またはテトラゾリルを表し、
Yは、−CHR2−CHR2−または−CR2=CR2−を表し、
Qは、O、OH、NH、NH2、NR2R3、C=O、CHOH、CHNH2、C=NH、CHOR2またはCNR2R3を表し、
R1は、分枝または非分枝のアルキルシクロアルキル、アルカリールまたはアルクヘテロアリールを表し、これらはそれぞれXによって単置換または多置換されていて、
R2は、Hまたは直鎖または分枝のアルキルまたはアルカリールであり、
R3は、HまたはR2であり、
そして
mおよびnは、相互に独立して1、2または3を表す、
で表される前記化合物、それらの塩、溶媒和物、ラセミ体、エナンチオマーおよびジアステレオマーならびに全ての比率におけるそれらの混合物に関する。
式Iで表わされる化合物およびそれらの生理学的に受容可能な塩および溶媒和物は良好に耐容されるとともに、それらが中枢神経系に対する作用を有するために、価値ある薬理学的性質を有することが見出された。これらの化合物は、5−HT2A受容体に対して強力な親和性を有し、そして、5−HT2A受容体アンタゴニスト作用性を示す。
同様の5−HT2アンタゴニスト作用を示す他の化合物は、例えばEP0320983に記載されている。
WO 99/11641には、フェニルインドール誘導体として5−HT2−アンタゴニスト作用性を有するものが記載されている。
これらはまた、WO99/11641、2頁、24〜30行に記載されているような心臓血管系疾患および錐体外路症候群の処置にも適している。
本発明の化合物はまた、眼圧の減少および緑内障の処置に適している。これらの化合物はまた、動物へのエルゴバリンの投与における中毒現象の予防および処置にも適している。
本化合物はさらにまた、心臓血管系の障害の処置にも適している(WO99/11641、3頁、14〜15行)。本発明による化合物はまた、精神分裂症の処置において、他の活性成分と一緒に使用することもできる。好適な他の活性成分には、WO99/11641、13頁、20〜26行に記載されている化合物がある。
それらはまた、他の医薬的活性成分を製造するための中間体として使用することができる。
したがって、本発明は、式Iで表わされる化合物および請求項1に記載の式Iで表わされる化合物の製造方法に関する。
本発明は、医薬としての請求項1に記載の式Iの化合物および生理学的に受容可能なそれらの塩および溶媒和物に関する。
とくに本発明は、医薬としての請求項1に記載の式Iの化合物および生理学的に受容可能なそれらの塩および溶媒和物のうち、5−HT2A受容体−アンタゴニスト作用を有するものに関する。
1回より多く現れる全ての基については、それらの意味は互いに独立している。
基R2はアルキルまたはアルカリールを表し、1個〜12個、好ましくは1、2、3、4、5、6、7または8個、とくに1個または2個のC原子を有する。したがって、Alkylは、とくに、例えば、メチルを表し、さらにエチル、n−プロピル、イソプロピル、n−ブチル、sec−ブチルもしくはtert−ブチルを表し、さらにまたペンチル、1−、2−または3−メチルブチル、1,1−、1,2−または2,2−ジメチルプロピル、1-エチルプロピル、ヘキシル1−、2−、3-または4−メチルペンチル、1,1−、1,2−、1,3−、2,2−、2,3−または3,3−ジメチルブチル、1−または2−エチルブチル、1エチル−1−メチルプロピル、1−エチル−2−メチルプロピル、1,1,2−または1,2,2−トリメチルプロピルを表し、さらにトリフルオロメチルまたはペンタフルオロエチルを表す。アルカリールは、好ましくはアルキルフェニル、とくにベンジルまたはフェネチルを表す。
Qは好ましくはC=O、CHOHまたはCHNH2を表す。
Xは好ましくはF、Cl、Br、CN、OCN、COR2、COOR2、CONH2またはイミダゾリルを表し、とくにF、Cl、CN、COORまたはCONH2を表す。
Yで定義される基は、好ましくは置換されていないC原子におけるNおよび芳香環における置換されているC原子に連結される。
mおよびnは、好ましくは1を表す。
式Iの化合物におけるピペリジニル基の基Qへの結合は、好ましくは3位または4位を介してなされ、とくに4位を介してなされる。
式I7の化合物はとくに好ましい。
所望により、請求項に記載の方法の出発物質は、これらを反応混合物から単離せずに、さらに直ちに式Iで表わされる化合物に変換することで、その場で生成させることができる。他方、反応を段階的に行うこともできる。
TLC:酢酸エチル/メタノール 8:2 RF:0.2
融点:198.0−199.0°C
TLC:酢酸エチル/メタノール 8:2 RF:0.4
融点:132.0−133.0°C
7−(1−{1−[2−(4−フルオロフェニル)エチル]ピペリジン−4−イル}メタノイル)−1H−インドール−3−カルボニトリル塩酸の合成
TLC:酢酸エチル/メタノール 8:2 RF:0.5
融点:274−276°C
1−(2,3−ジヒドロ−1H−インドール−7−イル)−1−{1−[2−(4−フルオロフェニル)エチル]ピペリジン−4−イル}メタノールの合成
TLC:酢酸エチル/メタノール 8:2 RF:0.2
融点:151.5〜153.0°C
2,2,2−トリフルオロ−1−[7−({1−[2−(4−フルオロフェニル)エチル]ピペリジン−4−イル}ヒドロキシメチル)−1H−インドール−3−イル]エタノンの合成
TLC:酢酸エチル/メタノール 8:2 RF:0.2
1−[7−(ジメチルアミノ−{1−[2−(4−フルオロフェニル)エチル]ピペリジン−4−イル}メチル)−1H−インドール−3−イル]−2,2,2−トリフルオロエタノンの合成
TLC:酢酸エチル/メタノール 8:2 RF:0.1
例A 注射バイアル
式Iの活性成分100gとリン酸水素二ナトリウム5gとの二回蒸留水3lに溶解した溶液を2Nの塩酸を使ってpHを6.5に調節し、無菌濾過し、注射用バイアルに移し、無菌条件で凍結乾燥し、無菌条件で封じる。各注射用バイアルは活性成分5mgを含む。
式Iの活性成分20gと大豆レシチン100gとココアバター1400gの混合物を溶融し、鋳型に注ぎ、冷却する。各座薬は活性成分20mgを含有する。
二回蒸留水940ml中、の式Iの活性成分1gとNaH2PO4・2H2O 9.38g、NaH2PO4・12H2O 28.48g、塩化ベンザルコニウム0.1gから溶液を調製する。そのpHを6.8に調節し、その溶液を1lにし、照射によって無菌にする。この溶液を点眼剤の形で使用できる。
式Iの活性成分500mgをワセリン99.5gとを無菌条件で混合する。
式Iの活性成分1kg、乳糖4kg、馬鈴薯澱粉1.2kg、タルク0.2kgおよびステアリン酸マグネシウムの混合物を、各錠剤が活性成分を10mg含むように通常の方法で打錠する。
例Eと同様に錠剤を打錠し、続いてスクロース、馬鈴薯澱粉、タルク、トラガカントおよび着色剤で通常の方法で糖衣錠を作製する。
式Iの活性成分2kgを、硬ゼラチンカプセルに、活性成分を20mg含むように、通常の方法で導入する。
式Iの活性成分1kgを二回蒸留水60lに溶解した溶液を無菌状態で濾過し、アンプルに移し、無菌条件下で凍結乾燥し、無菌条件で封じる。各アンプルは活性成分を10mg含む。
Claims (8)
- 下記式Iの化合物:
Xは、HまたはF、Cl、Br、I、CN、OCN、SCN、COR2、COOR2、CONR2R3、イミダゾリル、ピラゾリル、トリアゾリル、またはテトラゾリルを表し、
Yは、−CHR2−CHR2−または−CR2=CR2−を表し、
Qは、O、OH、NH、NH2、NR2R3、C=O、CHOH、CHNH2、C=NH、CHOR2またはCNR2R3を表し、
R1は、分枝または非分枝の、アルキルシクロアルキル、アルカリールまたはアルクヘテロアリールを表し、これらはそれぞれXによって単置換または多置換されていて、
R2は、Hまたは直鎖または分枝のアルキルまたはアルカリールであり、
R3は、HまたはR2であり、
そして
mおよびnは、相互に独立して1、2または3を表す、
で表される前記化合物、それらの塩、溶媒和物、ラセミ体、エナンチオマーおよびジアステレオマーならびに全ての比率におけるそれらの混合物。 - 医薬としての、請求項1または2に記載の式Iの化合物ならびにそれらの生理学的に受容可能な塩および溶媒和物。
- 5−HT2A受容体アンタゴニスト活性を有する医薬としての、請求項1または2に記載の式Iの化合物ならびに生理学的に受容可能なそれらの塩および溶媒和物。
- 精神病、精神分裂病、うつ病、神経学的障害、記憶障害、パーキンソン病、筋萎縮性側索硬化症、アルツハイマー病、ハンチントン病、摂食障害(例えば、過食症)、パニック発作、拒食症、睡眠障害(例えば、睡眠時無呼吸)、月経前症候群の処置、脳梗塞現象の影響(例えば心臓発作および脳虚血)の予防および治療、および/または強迫性障害(OCD)にポジティブな影響を与えるための、請求項4に記載の医薬。
- 少なくとも1種の請求項5に記載の医薬および任意に賦形剤および/または助剤を含み、さらに任意に他の活性成分を含む医薬製剤。
- 5−HT2A受容体アンタゴニスト活性を有する医薬の製造における、請求項1または2に記載の化合物および/または生理学的に受容可能なそれらの塩および溶媒和物の使用。
- 精神病、精神分裂病、うつ病、神経学的障害、記憶障害、パーキンソン病、筋萎縮性側索硬化症、アルツハイマー病、ハンチントン病、摂食障害(例えば、過食症)、パニック発作、拒食症、睡眠障害(例えば、睡眠時無呼吸)、月経前症候群の処置、脳梗塞現象の影響(例えば心臓発作および脳虚血)の予防および治療、および/または強迫性障害(OCD)にポジティブな影響を与えるための医薬の製造における、請求項7に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004010132A DE102004010132A1 (de) | 2004-02-27 | 2004-02-27 | Piperidinderivate |
PCT/EP2005/001446 WO2005082886A1 (de) | 2004-02-27 | 2005-02-14 | Piperidinderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007523930A true JP2007523930A (ja) | 2007-08-23 |
Family
ID=34853893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007500098A Ceased JP2007523930A (ja) | 2004-02-27 | 2005-02-14 | ピペリジン誘導体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7834032B2 (ja) |
EP (1) | EP1718634A1 (ja) |
JP (1) | JP2007523930A (ja) |
AR (1) | AR047899A1 (ja) |
AU (1) | AU2005217043B2 (ja) |
CA (1) | CA2557489A1 (ja) |
DE (1) | DE102004010132A1 (ja) |
WO (1) | WO2005082886A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085892A1 (en) * | 2001-04-20 | 2002-10-31 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2003068772A1 (en) * | 2002-02-18 | 2003-08-21 | Glaxo Group Limited | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1280421C (en) * | 1985-07-02 | 1991-02-19 | Albert A. Carr | 1,4-disubstituted piperidinyl derivatives |
JPH02138214A (ja) | 1987-12-10 | 1990-05-28 | Merrell Dow Pharmaceut Inc | 不安を治療する方法 |
US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
US5618824A (en) | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
GB9718712D0 (en) | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
TWI249526B (en) | 1998-03-13 | 2006-02-21 | Aventis Pharma Inc | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
EP1339708A2 (en) * | 2000-11-20 | 2003-09-03 | Scios Inc. | Indole-type inhibitors of p38 kinase |
-
2004
- 2004-02-27 DE DE102004010132A patent/DE102004010132A1/de not_active Withdrawn
-
2005
- 2005-02-14 JP JP2007500098A patent/JP2007523930A/ja not_active Ceased
- 2005-02-14 US US10/590,912 patent/US7834032B2/en not_active Expired - Fee Related
- 2005-02-14 EP EP05715322A patent/EP1718634A1/de not_active Withdrawn
- 2005-02-14 WO PCT/EP2005/001446 patent/WO2005082886A1/de active Application Filing
- 2005-02-14 AU AU2005217043A patent/AU2005217043B2/en not_active Ceased
- 2005-02-14 CA CA002557489A patent/CA2557489A1/en not_active Abandoned
- 2005-02-25 AR ARP050100705A patent/AR047899A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085892A1 (en) * | 2001-04-20 | 2002-10-31 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2003068772A1 (en) * | 2002-02-18 | 2003-08-21 | Glaxo Group Limited | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
Also Published As
Publication number | Publication date |
---|---|
AU2005217043B2 (en) | 2011-06-23 |
US7834032B2 (en) | 2010-11-16 |
DE102004010132A1 (de) | 2005-09-15 |
AU2005217043A1 (en) | 2005-09-09 |
WO2005082886A1 (de) | 2005-09-09 |
US20070197596A1 (en) | 2007-08-23 |
AR047899A1 (es) | 2006-03-01 |
EP1718634A1 (de) | 2006-11-08 |
CA2557489A1 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4740115B2 (ja) | 置換ピラゾール | |
JP3220266B2 (ja) | アザヘテロサイクリルメチル−クロマン | |
JP4316794B2 (ja) | イソキノリン誘導体及び医薬 | |
JP3834098B2 (ja) | ベンゾニトリル類およびベンゾフルオリド類 | |
WO1997028130A1 (fr) | Derives de l'isoquinoline et medicaments associes | |
IL109234A (en) | History of indole, their preparation and pharmaceutical preparations containing them | |
JP4740116B2 (ja) | 精神疾患および神経障害の処置のための5−ht受容体アンタゴニスト | |
PL217872B1 (pl) | Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól | |
JPH11508283A (ja) | ベンゾフリル誘導体類及びそれらの用途 | |
JP4354652B2 (ja) | ベンゾイルピリダジン | |
MXPA05002836A (es) | Indoles 2,4-sustituidos y su uso como moduladores 5-ht6. | |
JP4833832B2 (ja) | ピラゾール化合物 | |
JP4958379B2 (ja) | 1−[アルキル],1−[(ヘテロアリール)アルキル]および1−[(アリール)アルキル]−7−ピリジニル−イミダゾ[1,2−a]ピリミジン−5(1H)−オン誘導体 | |
JP2006527707A (ja) | セロトニン再取り込み阻害剤としてのインドール誘導体 | |
JP4624979B2 (ja) | 抗うつ薬および抗不安薬としてのベンゾフラノキシエチルアミン | |
JP2007506677A (ja) | 特に過敏性腸症候群の処置および/または予防のためのκアゴニスト | |
JP2006527706A (ja) | セロトニン再取り込み阻害剤としてのインドール誘導体 | |
JP2006522039A (ja) | 置換ピラゾール化合物 | |
EP0993458B1 (de) | 3-benzylpiperidine | |
JP4563817B2 (ja) | インドール誘導体およびその5−ht配位子としての使用 | |
JP2007523930A (ja) | ピペリジン誘導体 | |
JP4664275B2 (ja) | ベンゾフラン誘導体ならびに抗うつ剤および抗不安剤としてのそれらの使用 | |
PT94950A (pt) | Processo para a preparacao de derivados benzopiranos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080213 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110726 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110823 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20111220 |